Limb Perfusion Contraindications
Limb Perfusion Contraindications - Related Videos
05:27
Establishing In Situ Closed Circuit Perfusion of Lower Abdominal Organs and Hind Limbs in Mice
0 Views •
2020
A protocol is described for in situ perfusion of the mouse lower body, including the bladder, the prostate, sex organs, bone, muscle and foot skin.
08:19
The Mouse Isolated Perfused Kidney Technique
0 Views •
Cited by 24 •
2016
The mouse isolated perfused kidney (MIPK) is a technique for keeping a mouse kidney under ex vivo conditions perfused and functional for 1 hr. The buffers and surgical technique are described in detail.
04:20
Non-Invasive Limb Ischemic Preconditioning in a Rat Model for Neuroprotection
0 Views •
2025
Source: Brandli, A. Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents. J. Vis. Exp. (2015)This video demonstrates a non-invasive limb ischemic preconditioning protocol in rats to induce systemic neuroprotection. The procedure involves controlled arterial occlusion and reperfusion, triggering cellular stress pathways that release protective factors. These factors enhance resistance to ischemic and metabolic injuries in distant organs such as the brain and retina.
06:05
DiI Perfusion as a Method for Vascular Visualization in Ambystoma mexicanum
0 Views •
Cited by 3 •
2017
Using a lipophilic 1,1'-Dioctadecy-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) staining technique, Ambystoma mexicanum can undergo vascular perfusion to allow for easy visualization of the vasculature.
04:44
Antegrade Perfusion Model: An Ex Vivo Technique to Perfuse Isolated Mouse Heart
0 Views •
2025
This video describes an antegrade perfusion technique of an isolated mouse heart during which a perfusate is injected through the left ventricle, and eventually, it perfuses the entire myocardium. This method can be used to isolate cardiomyocytes from murine models and generate decellularized hearts for further downstream applications.
FAQs
Vascular integrity determines whether the limb can receive and retain regional treatment safely. Arterial impairment may limit delivery to target tissues, while venous impairment can hinder drainage and alter local drug distribution. Either problem can increase tissue injury or produce an unpredictable pharmacologic effect, so assessment of both arterial and venous flow is essential before treatment.
Impaired arterial flow can prevent adequate circulation of the pharmacologic agent through the extremity, reducing treatment reliability. Impaired venous flow may interfere with normal outflow and contribute to abnormal local exposure. These mechanisms differ, but both make drug distribution less predictable and can increase the risk that perfused tissues will be damaged.
The treatment depends on temporarily separating limb blood flow from systemic circulation. If that separation cannot be achieved, the regional agent may enter the rest of the body, increasing systemic exposure beyond the intended local treatment. This risk is especially important in pharmacology because regional delivery is designed to concentrate drug action in the affected extremity.
Severe tissue damage can reduce the limb's ability to tolerate additional pharmacologic and procedural stress, increasing the possibility of local injury. Infection also represents a treatment-related concern during patient selection. These findings therefore require careful evaluation before proceeding, because the expected benefit of regional therapy must be weighed against the condition of the tissues being treated.
Organ function is part of the pre-treatment safety assessment because regional delivery does not eliminate all concerns about systemic toxicity. Clinicians should review whether the patient can tolerate the pharmacologic agent and the procedure, alongside vascular status, infection risk, and tissue condition. This broader assessment supports appropriate selection and helps limit treatment-related toxicity.
Screening examines three related areas: the patient's organ function and ability to tolerate the procedure, the limb's arterial and venous circulation, and treatment-specific factors such as whether the circulation can be isolated. Clinicians also assess tissue damage and infection risk. Integrating these findings helps determine suitability and supports safer regional pharmacotherapy in cancer and vascular care.